Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Masimo (NASDAQ: MASI) today announced that Vanderbilt University Medical Center (VUMC), a renowned healthcare facility in ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Apple won the case, though was only awarded a nominal $250, which is the smallest amount it was possible for the court to order. In other words, yes Masimo did in infringe Apple’s patents, but there ...

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will ...

Apple and Masimo’s legal battle over the Apple Watch’s Blood Oxygen sensing feature continues this week as both firms meet in ...

Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.